A Rutgers professor’s novel research into targeting and silencing defective, disease-causing RNA molecules has led to the launch of Ceptur Therapeutics, a startup that has raised $75 million in Series A funding.
Research in the News
Novel RNA Research, Invention, and Startup Born at Rutgers University Receives $75 Million in Series A Funding
- Click for News Details
- Faculty Referenced: Gunderson, Samuel I.